PuraPharm Appoints S.F. Express (順豐速運) as Warehousing and Logistics Delivery Partner for CCMG Business

PuraPharm Corporation Limited (“PuraPharm” or the “Group”, stock code: 1498), a leading Hong Kong-based Chinese medicine company specialising in the research and development, production and sale of Concentrated Chinese Medicine Granules (“CCMG”) products under the “Nong’s^® (農本方^®)” brand, announced that it has entered into three-year strategic cooperative agreements with Chengdu Shunyifeng Pharmaceuticals Co., Ltd. (成都順意豐醫藥有限公司) (“Chengdu S.F.”) and S.F. Pharmaceutical Supply Chain Co., Ltd. (順豐醫藥供應鏈有限公司) (“S.F. Supply Chain”), subsidiaries of S.F. Express (順豐速運) (“S.F. Express”), one of the leaders in China’s express delivery industry, to provide pharmaceutical warehousing and logistics delivery services to its CCMG products in China.
The Group believes that it can strengthen its supply chain management from S.F. Express’ certified Good Supply Practice (“GSP”) pharmaceutical warehouse network, where products will be delivered directly to S.F. Express’ pharmaceutical warehouses. Backed by S.F. Express’ comprehensive and professional pharmaceutical logistics platform and country-wide network, the Group can increase the efficiency of delivery of its CCMG products to the customers, which is essential to the expansion of its CCMG business in China.

Mr. Abraham Chan, Founder, Chairman, Chief Executive Officer and Executive Director of PuraPharm, said, “We currently market and distribute CCMG products in China through direct sales channels to hospitals and medical institutions, and have also appointed third party distributors such as Sinopharm Group Co Ltd., Heilongjiang ZBD Pharmaceutical Co., Ltd. and Yunnan Baiyao Group Co., Ltd. Our extensive sales and distribution network stretch out to more than 20 provinces in China.”

Mr. Chan added, “It is our hope that this partnership will give us leverage on S.F. Express’ highly effective warehouse network to achieve timely deliveries within short distance in order to create a better consumption experience and greatly increase the degree of satisfaction of customers. In addition to expanding our customer outreach in China, we also hope to optimise our marketing and sales efficiency, as well as upgrade our supply chain network, thus enabling the Group to expand market coverage and sales network, and further enhance its market penetration in China. Along with our strong R&D capabilities, we will continue to develop and introduce new products so as to maintain our market leader position and capture enormous business opportunities in Mainland China.”